Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 13,436 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Insmed Trading Down 0.5 %

INSM opened at $72.87 on Thursday. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The company has a market cap of $10.83 billion, a P/E ratio of -13.93 and a beta of 1.11. The business’s 50-day simple moving average is $74.77 and its 200-day simple moving average is $51.39.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. During the same quarter in the prior year, the company earned ($1.78) EPS. The firm’s revenue was up 17.0% compared to the same quarter last year. As a group, equities research analysts expect that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

Several hedge funds and other institutional investors have recently bought and sold shares of INSM. Victory Capital Management Inc. boosted its stake in Insmed by 21.4% in the fourth quarter. Victory Capital Management Inc. now owns 18,797 shares of the biopharmaceutical company’s stock valued at $583,000 after acquiring an additional 3,311 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Insmed by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,128,436 shares of the biopharmaceutical company’s stock valued at $34,970,000 after purchasing an additional 28,629 shares during the last quarter. QRG Capital Management Inc. acquired a new stake in shares of Insmed in the 4th quarter valued at about $246,000. Norges Bank purchased a new position in Insmed during the 4th quarter worth approximately $45,029,000. Finally, UBS Group AG increased its position in Insmed by 145.6% during the fourth quarter. UBS Group AG now owns 300,181 shares of the biopharmaceutical company’s stock worth $9,303,000 after buying an additional 177,981 shares during the period.

Analyst Ratings Changes

A number of equities analysts recently commented on INSM shares. Bank of America restated a “buy” rating and set a $83.00 target price on shares of Insmed in a report on Friday, July 5th. JPMorgan Chase & Co. raised their price objective on shares of Insmed from $55.00 to $72.00 and gave the company an “overweight” rating in a research note on Thursday, June 20th. The Goldman Sachs Group upped their target price on shares of Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. TD Cowen raised their price target on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.19.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.